Phase 4 N=72 Randomized Double-blind Basic Science

Empagliflozin and Hepatic Glucose Metabolism

Hepatic Glucose Metabolism

Bottom Line

View on ClinicalTrials.gov: NCT03193684 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2024

Primary outcome: Primary: Effect of Empagliflozin on Autonomic Nervous System — 480; 621; 355; 635 ng/min

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Empagliflozin 25 MG (Drug); Control (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: The University of Texas Health Science Center at San Antonio
Primary completion: Jan 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Effect of Empagliflozin on Autonomic Nervous System	480; 621; 355; 635	—
SECONDARY Hepatic Glucose Production	2.57; 2.63; 3.15; 2.50	—

Summary

the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake

Eligibility Criteria

Inclusion Criteria

eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy

Exclusion Criteria

eGFR <60 T2DM patients on insulin, GLP-1 RA or SGLT2 treatment Major organ disease type 1 diabetes

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03193684). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.